The best of EULAR 2016

Research

By Nicola Garrett

17 Jun 2016

At a wrap up session on Saturday afternoon Robert Landewè presented the clinical highlights from this year’s conference across the spectrum of rheumatology diseases. We’ve given you the links to each of the abstracts that made it into his clinical highlights.

Osteoarthritis:

RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE CLINICAL EFFICACY AND STRUCTURE MODIFYING PROPERTIES OF SUBCUTANEOUS ETANERCEPT (ETN) IN PATIENTS WITH EROSIVE INFLAMMATORY HAND OSTEOARTHRITIS (OA)

EFFECT OF ETANERCEPT ON SYNOVITIS AND BONE MARROW LESIONS IN EROSIVE HAND OSTEOARTHRITIS

Scleroderma:

THE SEROTONIN RECEPTOR 2 INHIBITOR TERGURIDE HAS BENEFICIAL EFFECTS ON SKIN FIBROSIS: RESULTS FROM A PHASE 2 PROOF OF CONCEPT STUDY

Systemic Lupus:

EFFICACY AND SAFETY OF SUBCUTANEOUS BELIMUMAB PLUS STANDARD CARE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) WITH LOW COMPLEMENT AND POSITIVE ANTI-DSDNA

IMPACT OF BELIMUMAB USE ON FLARES AMONG PATIENTS DIAGNOSED WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) IN A US COMMERCIALLY INSURED DATABASE: 2010-2014

ANIFROLUMAB, AN ANTI-INTERFERON-ALPHA RECEPTOR MONOCLONAL ANTIBODY, IN MODERATE TO SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

Vasculitis:

DOES ADDING AZATHIOPRINE TO GLUCOCORTICOID INDUCTION INCREASE THE REMISSION RATE AND PREVENT RELAPSES IN PATIENTS WITH SYSTEMIC NECROTIZING VASCULITIDES WITHOUT POOR-PROGNOSIS FACTORS? A MULTICENTER, DOUBLE-BLIND RANDOMIZED CONTROLLED TRIAL

Gout:

MEDICATION TAKING BEHAVIOUR OF ALLOPURINOL TREATMENT AMONG PATIENTS WITH GOUT: A RETROSPECTIVE COHORT STUDY IN THE CLINICAL PRACTICE RESEARCH DATALINK (CPRD)

HYPERURICEMIA INCREASES MORTALITY ONLY IN PATIENTS WITH GOUT AND EXISTING CARDIOVASCULAR DISEASE. A PROSPECTIVE ANALYSIS FROM THE BUSSELTON HEALTH STUDY

PsA:

BIMEKIZUMAB, A MONOCLONAL ANTIBODY THAT INHIBITS BOTH IL-17A AND IL-17F, PRODUCES A PROFOUND RESPONSE IN BOTH SKIN AND JOINTS: RESULTS OF AN EARLY-PHASE, PROOF-OF-CONCEPT STUDY IN PSORIATIC ARTHRITIS

Axial Spondyloarthritis:

EFFECT OF COMEDICATION WITH CONVENTIONAL SYNTHETIC DMARDS ON TNF INHIBITORS-RETENTION IN PATIENTS WITH SPONDYLOARTHRITIS: A PROSPECTIVE COHORT

ARE INDIVIDUAL OR COUNTRY LEVEL SOCIO-ECONOMIC DETERMINANTS RELATED TO DISEASE ACTIVITY AND SELF-REPORTED PHYSICAL FUNCTION IN PATIENTS WITH SPONDYLOARTHRITIS? RESULTS FROM MULTI-NATIONAL CROSS-SECTIONAL STUDY ASAS-COMOSPA

MRI LESIONS ORIGINATING FROM EITHER AXSPA OR DEGENERATION ARE RELATED TO SITE OF PAIN IN PATIENTS WITH CHRONIC BACK PAIN INCLUDED IN THE SPACE-COHORT

THE ASSOCIATION OF EXTRA-ARTICULAR MANIFESTATIONS WITH DISEASE DURATION IN AXIAL SPA: RESULTS FROM THE (BE-) GIANT COHORT AND THE ASPECT STUDY.

DOES THE PRESENCE OF MULTIPLE SPA-FEATURES IN PATIENTS WITH CHRONIC BACK PAIN ALWAYS LEAD TO DIAGNOSIS OF AXIAL SPONDYLOARTHRITIS?

TOFACITINIB IN PATIENTS WITH ANKYLOSING SPONDYLITIS: A PHASE 2, 16-WEEK, RANDOMISED, PLACEBO-CONTROLLED, DOSE-RANGING STUDY

EFFECT OF SECUKINUMAB, AN INTERLEUKIN-17A INHIBITOR, ON SPINAL RADIOGRAPHIC CHANGES THROUGH 2 YEARS IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: RESULTS OF THE PHASE 3 STUDY, MEASURE 1

EFFECT OF COMEDICATION WITH CONVENTIONAL SYNTHETIC DMARDS ON TNF INHIBITORS-RETENTION IN PATIENTS WITH SPONDYLOARTHRITIS: A PROSPECTIVE COHORT

RA:

ULTRASOUND IN THE MANAGEMENT OF RHEUMATOID ARTHRITIS: RESULTS FROM THE RANDOMIZED CONTROLLED ARCTIC TRIAL

PREDICTION OF FLARE AFTER STOPPING TNF-INHIBITOR BY BASELINE ULTRASONOGRAPHY AND PATIENT CHARACTERISTICS IN RHEUMATOID ARTHRITIS PATIENTS WITH LOW DISEASE ACTIVITY : 12-MONTH RESULTS.

RADIOGRAPHIC PROGRESSION IN RHEUMATOID ARTHRITIS PATIENTS TAPERING TNF INHIBITORS IS PRIMARILY DRIVEN BY MEAN DISEASE ACTIVITY OVER TIME, NOT SO MUCH BY FLARING OR LOWER TNF INHIBITOR EXPOSITION

FIVE YEAR OUTCOMES OF REMISSION STEERED TREATMENT INCLUDING DRUG TAPERING STRATEGIES IN EARLY ARTHRITIS PATIENTS

PREVENTION OF RHEUMATOID ARTHRITIS BY B CELL DIRECTED THERAPY IN THE EARLIEST PHASE OF THE DISEASE: THE PRAIRI STUDY

A COST-EFFECTIVENESS ANALYSIS OF DIFFERENT INTENSIVE COMBINATION THERAPIES FOR EARLY RHEUMATOID ARTHRITIS: 1 YEAR RESULTS OF THE CARERA TRIAL

HOW MUCH OF A BARRIER IS EXCESS WEIGHT AND SMOKING FOR ACHIEVING SUSTAINED REMISSION IN EARLY RA? RESULTS FROM THE CANADIAN EARLY ARTHRITIS COHORT

PREDICTION OF NON-RESPONSE TO METHOTREXATE THERAPY IN THE RHEUMATOID ARTHRITIS MEDICATION STUDY (RAMS)

SAFETY AND EFFICACY OF ABT-494, A NOVEL SELECTIVE JAK1 INHIBITOR, IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE

FILGOTINIB (GLPG0634), AN ORAL JAK1 SELECTIVE INHIBITOR IS EFFECTIVE IN COMBINATION WITH METHOTREXATE IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: RESULTS FROM A 24-WEEK PHASE 2B DOSE RANGING STUDY

RANDOMIZED, DOUBLE-BLIND STUDY COMPARING CHS-0214 WITH ETANERCEPT IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS (RA) DESPITE METHOTREXATE (MTX) THERAPY

Already a member?

Login to keep reading.

OR

Email me a login link

Not a member yet?

Join now to stay up to date with the latest clinical and medico-political news relevant to your specialty. the limbic is intended for practicing healthcare professionals only.

title*

first name*

last name*

country*

Postcode where you practice*

Email*

password* Forgot password?

Password must contain at least 8 characters including 1 letter and 1 number.

ahpra number* Find my AHPRA number

primary area of interest*

Our newsletter is a quick and easy to read summary of the latest clinical and medico-political news relevant to your specialty. It may contain advertising and educational or promotional material from carefully selected industry partners including pharmaceutical companies, government agencies and not-for-profit organisations. Your details will not be shared with any other party.

I would like to receive the limbic newsletter

I have read and agree to the limbic Terms and Conditions & Privacy Policy